Berthelsen Program for Restoration of Intestinal Microbiota (B-PRIM)
Study Information: B-PRIM, often called Fecal Transplantation, is conducting clinical trials for patients with Recurrent Clostridium Difficile Infection (CDI). The UT Health School of Public Health's Center for Infectious Diseases established PRIM in 2013 and, in affiliation with Kelsey Research Foundation and Kelsey-Seybold Clinic, has treated more than 100 patients with recurrent CDI. To be evaluated for B-PRIM, subjects should have:
- At least 3 documented recurrences of CDI in the past year inclusive of the recurrent CDI episode or at least 2 episodes of severe CDI resulting in hospitalization;
- A positive C. difficile toxin test report for most recent CDI (within last 60 days) and at least 2 positive additional C. difficile test reports; and
- Completed at least 2 rounds of standard-of-care antibiotic (vancomycin or fidaxomicin) therapy.
For additional study information click here.
Learn more about B-PRIM at: